Intraperitoneal drug therapy: An advantage

Current Clinical Pharmacology

Volumn 5, Issue 2, 2010, Pages 82-88

  Chaudhary, Kunal ^a,b   Haddadin, Shadi ^b   Nistala, Ravi ^b   Papageorgio, Chris ^b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF MISSOURI   (United States)

Author keywords

Intraperitoneal; IP drug therapy; Peritoneal cavity; Peritonitis

Indexed keywords

ADRENALIN; ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; CEFAZOLIN; CEFTAZIDIME; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; GENTAMICIN; HEPARIN; ICODEXTRIN; INSULIN; MELPHALAN; PACLITAXEL; RECOMBINANT ERYTHROPOIETIN; SMALL INTERFERING RNA; VANCOMYCIN; VASOPRESSIN;

ABDOMINAL PRESSURE; CANCER THERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DIGESTIVE SYSTEM CANCER; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG TRANSPORT; DRUG TUMOR LEVEL; GENE THERAPY; GYNECOLOGIC CANCER; HUMAN; HYPERTHERMIC THERAPY; INTRAPERITONEAL DRUG ADMINISTRATION; KIDNEY FAILURE; NONHUMAN; OVARY CANCER; PERITONEAL CAVITY; PERITONEAL DIALYSIS; PERITONITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTINEOPLASTIC AGENTS; DRUG DELIVERY SYSTEMS; HUMANS; INJECTIONS, INTRAPERITONEAL; PERITONEAL CAVITY; PERITONEAL NEOPLASMS; PERITONITIS;

EID: 77951579146     PISSN: 15748847     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488410791110779     Document Type: Review

References (71)

1. Popovich R, Moncreif J, Nolph K. Continuous ambulatory peritoneal dialysis. Artif Organs 1978; 2: 84-86.
2. Dedrick RL, Myers CE, Bungay PM, DeVita VT. Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treat Rep 1978; 62: 1-11.
3. Kerr DJ, Young AM, Neoptolemos JP, et al. Prolonged intraperitoneal infusion of 5-fluorouracil using a novel carrier solution. Br J Cancer 1996; 74(12): 2032-2035
4. Rippe B. A three-pore model of peritoneal transport. Perit Dial Int 1993; 13 Suppl 2:S35-8.
5. Massry SG, Glassok RC, Eds. Textbook of Nephrology, 4th ed, Baltimore, Williams & Wilkins 2000; pp. 1529-1530
6. Pietrzak I, Hirszel P, Shostak A, Welch PG, Lee RE, Maher JF. Splanchnic volume, not flow rate, determines peritoneal permeability. ASAIO Trans 1989; 35(3): 583-587
7. Erbe RW, Greene JA Jr, Weller JM. Peritoneal dialysis during hemorrhagic shock. J App Physiol 1967; 22: 131-135
8. Rosengren BI, Rippe B. Blood flow limitation in vivo of small solute transfer during peritoneal dialysis in rats. J Am Soc Nephrol 2003; 14: 1599-2003.
9. Chagnac A, Herskovitz P, Weinstein T, et al. The peritoneal membrane in peritoneal dialysis patients: estimation of its functional surface area by applying stereologic methods to computerized tomography scans. J Am Soc Nephrol 1999; 10(2): 342-346
10. Chagnac A, Herskovitz P, Ori Y, et al. Effect of increased dialysate volume on peritoneal surface area among peritoneal dialysis patients. J Am Soc Nephrol 2002; 13: 2554-2559
11. Hosie KB, Gilbert J, Kerr DJ, Brown C, Peers E. Fluid dynamics in man of an intraperitoneal drug delivery solution 4% icodextrin. Drug Deliv 2001; 8: 9-12.
12. Hosie KB, Kerr DJ, Gilbert JA, et a;. A pilot study of adjuvant intraperitoneal 5-fluorouracil using 4% icodextrin as a novel carrier solution. Eur J Surg Oncol 2003; 29: 254-260.
13. Flessner MF, Lofthouse J, Williams A. Increasing peritoneal contact area during dialysis improves mass transfer. J Am Soc Nephrol 2001; 12(10): 2139-2145
14. Gotloib L, Shostack A, Jaichenko J. Ruthenium-red-stained anionic charges of rat and mice mesothelial cells and basal lamina: the peritoneum is a negatively charged dialyzing membrane. Nephron 1988; 48(1): 65-70.
15. rd ed, US, Springer Link 2009; pp. 865-866
16. Stoenoiu MS, De Vriese AS, Brouet A, et al. Experimental diabetes induces functional and structural changes in the peritoneum. Kidney Int 2002; 62(2): 668-678
17. Honda K, Hamada C, Nakayama M, et al. Impact of uremia, diabetes, and peritoneal dialysis itself on the pathogenesis of peritoneal sclerosis: a quantitative study of peritoneal membrane morphology. Clin J Am Soc Nephrol 2008; 3: 720-728
18. Gilbert JA, Peers EM, Brown CB, Beran Y. IP fluids dynamic of 4% icodextrin in non ESRD patients. Perit Dial Int (Abst) 1999; 19 (S 1): S79.
19. Sticca RP, Dach BW. Rationale for hyperthermia with intraoperative intraperitoneal chemotherapy agents. Surg Oncol Clin N Am 2003; 12(3): 689-701.
20. Dahl O, Dalene R, Schem BC, Mella O. Status of clinical hyperthermia. Acta Oncol 1999; 38: 863-873
21. Hahn GM, Braun J, Har-kedar I. Thermo chemotherapy: synergism between hyperthermia (42-43 degrees) and adriamycin (of bleomycin) in mammalian cell inactivation. Proc Natl Acad Sci USA 1975; 72(3): 937-940
22. Kusumoto T, Holden SA, Ara G, Teicher BA: Hyperthermia and platinum complexes: time between treatments and synergy in vitro and in vivo. Int J Hyperthermia 1995; 11(4): 575-586
23. Barlogie B, Corry PM, Drewinko B: In vitro thermochemotherapy of human colon cancer cells with cis dichlorodiammineplatinum (II) and mitomycin C. Cancer Res 1980; 40(4): 1165-1168
24. Urano M, Ling CC: Thermal enhancement of melphalan and oxiplatin cytology in vitro. Int J Hypertherm 2002; 18(4): 307-315
25. Jacquet P, Averbach A, Stuart OA, Chang D, Sugarbaker PH. Hyperthermic intraperitoneal doxorubicin: pharmacokinetics, metabolism, and tissue distribution in a rat model. Cancer Chemother Pharmacol 1998; 41(2): 147-154
26. Esquis P, Consolo D, Magnin G, et al. High intra-abdominal pressure enhances the penetration and antitumor effect of intraperitoneal cisplatin on experimental peritoneal carcinomatosis. Ann Surg 2006; 244(1): 106-112
27. Jacquet P, Stuart OA, Chang D, Sugarbaker PH. Effects of intra-abdominal pressure on pharmacokinetics and tissue distribution of doxorubicin after intraperitoneal administration. Anticancer Drugs 1996; 7(5): 596-603.
28. Pestieau SR, Schnake KJ, Stuart OA, Sugarbaker PH. Impact of carrier solutions on pharmacokinetics of intraperitoneal chemotherapy. Cancer Chemother Pharmacol 2001; 47(3): 269-276
29. Mohamed F, Sugarbaker PH. Carrier solutions for intraperitoneal chemotherapy. Surg Oncol Clin N Am 2003; 12(3): 813-824
30. Elias D, El Otmany A, Bonnay M, et al. Human pharmacokinetic study of heated intraperitoneal oxaliplatin in increasingly hypotonic solutions after complete resection of peritoneal carcinomatosis. Oncology 2002; 63(4): 346-352
31. Keshaviah P, Emerson PF, Vonesh EF, Brandes JC. Relationship between body size, fill volume, and mass transfer area coefficient in peritoneal dialysis. J Am Soc Nephrol 1994; 4: 1820-1826
32. Sugarbaker PH, Stuart OA, Carmignani CP. Pharmacokinetic changes induced by the volume of chemotherapy solution in patients treated with hyperthermic intraperitoneal mitomycin C. Cancer Chemother Pharmacol 2006; 57(5): 703-708
33. Molucon-Chabrot C, Isambert N, Benoit L, et al. Feasibility of using intraperitoneal epinephrine and cisplatin in patients with advanced peritoneal carcinomatosis. Anticancer Drugs 2006; 17(10): 1211-1217
34. Lindnér P, Heath D, Howell S, Naredi P, Hafström L. Vasopressin modulation of peritoneal, lymphatic, and plasma drug exposure following intraperitoneal administration. Clin Cancer Res 1996; 2(2): 311-317
35. Flessner MF, Lofthouse J, Zakaria ER. Improving contact area between the peritoneum and intraperitoneal therapeutic solutions. J Am Soc Nephrol 2001; 12(4): 807-813
36. Flessner MF, Lofthouse J, Williams A. Increasing peritoneal contact area during dialysis improves mass transfer. J Am Soc Nephrol 2001; 12(10): 2139-2145
37. Gelderblom H, Verweij J, van Zomeren DM, et al. Influence of Cremophor EL on the bioavailability of intraperitoneal paclitaxel. Clin Cancer Res 2002; 8: 1237-1241
38. Elias D, Bonnay M, Puizillou JM, et al. Heated intra-operative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis: pharmacokinetics and tissue distribution. Ann Oncol 2002; 13(2): 267-272
39. Steller MA, Egorin MJ, Trimble EL, et al. A pilot phase I trial of continuous hyperthermic peritoneal perfusion with high-dose carboplatin as primary treatment of patients with small-volume residual ovarian cancer. Cancer Chemother Pharmacol 1999; 43(2): 106-114
40. Lewis C, Lawson N, Rankin EM, et al. Phase I and pharmacokinetic study of intraperitoneal thio TEPA in patients with ovarian cancer. Cancer Chemother Pharmacol 1990; 26(4): 283-287
41. Wikes H, Howell S. Pharmacokinetics of hexamethylmelamine administered via the ip route in an oil emulsion vehicle. Cancer Treat Rep 1985; 69; 657-662
42. Bennett-Jones, Wass V, Mawson P, et al. A comparison of intraperitoneal and intravenous/oral antibiotics in CAPD peritonitis. Perit Dial Bull 1987; 7; 31-33
43. Piraino B, Bailie GR, Bernardini J, et al, ISPD Ad Hoc Advisory Committee. Perit Dial Int 2005; 25(2): 107-131 Peritoneal dialysis-related infections recommendations: 2005 update.
44. Mulhern JG, Braden GL, O'Shea MH, Madden RL, Lipkowitz GS, Germain MJ. Trough serum vancomycin level predicts the relapse of gram-positive peritonitis in peritoneal dialysis patients. Am J Kid Dis 1995; 25: 611-615
45. Moellering RC Jr. Pharmacokinetics of vancomycin. J Antimicrob Chemother 1984, 14 (Suppl D): 43-52.
46. Bunke C, Aronoff G, Brier ME, Sloan RS, Luft FC. Vancomycin kinetics during CAPD. Clin Pharmacol Ther 1983; 34: 631-637
47. Wong PN, Mak SK, Lee KF, Fung LH, Wong AK. A prospective study of vancomycin induced chemical peritonitis in CAPD patients. Perit Dial Int 1997; 17: 202-204
48. Shemin D, Maaz D, St Pierre D, Kahn SI, Chazan JA. Effect of aminoglycoside use on residual renal function in peritoneal dialysis patients. Am J Kidney Dis 1999; 34(1): 14-20.
49. Baker RJ, Senior H, Clemenger M, Brown EA. Empirical amino-glycosides for peritonitis do not affect residual renal function. Am J Kidney Dis 2003; 41(3): 670-765
50. Gorman T, Eisele G, Bailie GR. Intraperitoneal antibiotics effectively treat non-dialysis-related infections. Perit Dial Int 1995; 15: 283-284
51. Alberts DS, Liu PY, Hannigan EV, et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med 1996; 26: 1950-1955
52. Scheithauer W, Kornek GV, Marczell A, et al. Combined intravenous and intraperitoneal chemotherapy with fluorouracil + leucovorin vs fluorouracil + levamisole for adjuvant therapy of resected colon carcinoma. Br J Cancer 1998; 77: 1349-1354
53. Markman, M. An update on the use of intraperitoneal chemotherapy in the management of ovarian cancer. Cancer J 2009; 15(2): 105-109
54. Dedrick RL, Flessner MF. Pharmacokinetic problems in peritoneal drug administration: tissue penetration and surface exposure. J Natl Cancer Inst 1997; 89(7): 480-487
55. Van der Speeten K, Stuart OA, Sugarbaker PH. Pharmacokinetics and pharmacodynamics of perioperative cancer chemotherapy in peritoneal surface malignancy. Cancer J 2009; 15(3): 216-224
56. Lukas G, Brindle SD, Greengard P. The route of absorption of intraperitoneally administered compounds. J Pharmacol Exp Ther 1971; 178(3): 562-564
57. de Bree E, Theodoropoulos PA, Rosing H, et al. Treatment of ovarian cancer using intraperitoneal chemotherapy with taxanes: from laboratory bench to bedside. Cancer Treat Rev 2006; 32(6): 471-482
58. Markman M. Intraperitoneal antineoplastic drug delivery: rationale and results. Lancet Oncol 2004; 4: 277-283
59. Quellhorst E. Insulin therapy during peritoneal dialysis: pros and cons of various forms of administration. J Am Soc Nephrol 2002; 13 Suppl 1: S92-6.
60. Johnson CA, Amidon G, Reichert JE, Porter WR. Adsorption of insulin to the surface of peritoneal dialysis solution containers. Am J Kidney Dis 1983; 3(3): 224-228
61. Wideröe TE, Smeby LC, Berg KJ, Jörstad S, Svartås TM. Intraperitoneal (125I) insulin absorption during intermittent and continuous peritoneal dialysis. Kidney Int 1983; 23(1): 22-28
62. Tabata T, Shimada H, Emoto M, et al. Inhibitory effect of heparin and/or antithrombin III on intraperitoneal fibrin formation in continuous ambulatory peritoneal dialysis. Nephron 1990; 56(4): 391-395
63. Taylor CA 3rd, Kosorok MR, Zimmerman SW, Johnson CA. Pharmacokinetics of intraperitoneal epoetin alfa in patients on peritoneal dialysis using an 8-hour "dry dwell" dosing technique. Am J Kidney Dis 1999; 34(4): 657-662
64. Jones MR, Gehr TW, Burkart JM, et al. Replacement of amino acid and protein losses with 1.1% amino acid peritoneal dialysis solution. Perit Dial Int 1998; 18(2): 210-216
65. National Kidney foundation. K-DOQI clinical practice guidelines for nutrition in chronic renal failure. Am J Kidney Dis 2000; 35 (Suppl): S1-S104.
66. Deshane J, Siegal GP, Wang M, et al. Transductional efficacy and safety of an intraperitoneally delivered adenovirus encoding an anti-erbB-2 intracellular single-chain antibody for ovarian cancer gene therapy. Gynecol Oncol 1997; 64(3): 378-385
67. Hwang RF, Gordon EM, Anderson WF, Parekh D. Gene therapy for primary and metastatic pancreatic cancer with intraperitoneal retroviral vector bearing the wild-type p53 gene. Surgery 1998; 124(2): 143-150
68. Takakura M, Nakamura M, Kyo S, et al. Intraperitoneal administration of telomerase-specific oncolytic adenovirus sensitizes ovarian cancer cells to cisplatin and affects survival in a xenograft model with peritoneal dissemination. Cancer Gene Ther 2010; 17(1): 11-19
69. Landen CN, Merritt WM, Mangala LS, et al. Intraperitoneal delivery of liposomal siRNA for therapy of advanced ovarian cancer. Cancer Biol Ther 2006; 5(12): 1708-1713
70. Chen CJ, Moberly JB, Martis L. New developments in peritoneal dialysis solutions Adv Perit Dial 1998; 14: 116-119
71. Hoff CM, Shockley TR. Peritoneal dialysis in the 21st century: the potential of gene therapy. J Am Soc Nephrol 2002; 13 (Suppl 1): S117-24.